---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041387"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-09-03T20:55:07+00:00"
generated_at: "2026-09-03T20:59:45.274149+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# bioAffinity CEO to present at H.C. Wainwright conference Sept 14-16, 2026

## Summary
- President/CEO Maria Zannes will present corporate update and hold one-on-one investor meetings at H.C. Wainwright 28th Annual Global Investment Conference, Sept 14-16, 2026.
- Presentation to feature CyPath Lung diagnostic test commercial adoption and technology platform advancements for diagnostics and therapeutics.
- As of Sept 2, 2026, company had 600,736 common shares outstanding; aggregate market value ~$5.9M based on Nasdaq closing price.
- Live and archived webcast of presentation available Sept 11 at https://bit.ly/BIAFPresentation.

## SEC filing metadata
- accession: 0001493152-26-041387
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-09-03T20:55:07+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226041387/0001493152-26-041387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226041387/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041387
- JSON: https://secwatch.observer/filing/0001493152-26-041387.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.